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10 Abstract Endothelial dysfunction is a common feature of
11 hypertension, and it results from the imbalanced release of
12 endothelium-derived relaxing factors (EDRFs; in particular,
13 nitric oxide) and endothelium-derived contracting factors
14 (EDCFs; angiotensin II, endothelins, uridine adenosine
15 tetraphosphate, and cyclooxygenase-derived EDCFs). Thus,
16 drugs that increase EDRFs (using direct nitric oxide
17 releasing compounds, tetrahydrobiopterin, or L-arginine
18 supplementation) or decrease EDCF release or actions
19 (using cyclooxygenase inhibitor or thromboxane A2/pros-
20 tanoidQ1 receptor antagonists) would prevent the dysfunction.
21 Many conventional antihypertensive drugs, including
22 angiotensin-converting enzyme inhibitors, calcium channel
23 blockers, and third-generation β-blockers, possess the
24 ability to reverse endothelial dysfunction. Their use is
25 attractive, as they can address arterial blood pressure and
26 vascular tone simultaneously. The severity of endothelial
27 dysfunction correlates with the development of coronary
28 artery disease and predicts future cardiovascular events.
29 Thus, endothelial dysfunction needs to be considered as a
30 strategic target in the treatment of hypertension.
31Keywords Endothelium . Prostaglandin . Contraction .
32Free radical . Hypertensive rats
33Introduction
34The endothelium, the thin layer of cells that lines the inter
35ior surface of blood vessels, can be activated by various
36chemical and physical stimuli to simultaneously release
37endothelium-derived relaxing (EDRFs) and contracting
38(EDCFs) factors. EDRFs and EDCFs act as acute functional
39antagonists and exert opposing effects on the underlying
40vascular smooth muscles to control their tone (Fig. 1).
41When endothelial cells are exposed to a chronic elevation in
42arterial blood pressure, they age prematurely, their turnover
43is accelerated, and they are replaced by regenerated
44endothelial cells [1, 2]. However, the regenerated endothe-
45lium has an impaired ability to release EDRFs (endothelial
46dysfunction)—in particular, nitric oxide (NO) [3, 4]—
47which results in the weakening of the inhibitory brake to
48oppose the action of EDCFs, with ensuing prominence of
49endothelium-dependent contractions (constrictions) [5].
50Endothelial dysfunction can trigger a chain of undesired
51responses, including increases in platelet aggregation,
52expression of adhesion molecules, and vascular smooth
53muscle growth [1, 6]. Thus, a vicious cycle is established,
54ultimately contributing to thrombosis, inflammation, vas-
55cular remodeling, and atherosclerosis.
56Endothelial dysfunction has been demonstrated both in
57resistance arteries and conduit arteries of several hyperten-
58sive animals, including the spontaneously hypertensive rat
59(SHR) [7–9], the two-kidney one-clip model [10, 11],
60deoxycorticosterone acetate salt-treated animals [12], and
61the Dahl salt-sensitive rat [13, 14]. Evidence of endothelial
62dysfunction in human hypertension has been characterized
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63 by decreased forearm blood flow responses to endothelium-
64 dependent vasodilator agonists, such as acetylcholine and
65 bradykinin [15, 16], or by an increase in vasoconstrictor
66 response to locally administered nitric oxide synthase
67 inhibitors [17].
68 Endothelium-derived relaxing factors
69 The endothelium produces a range of EDRFs, the most
70 significant and well-characterized of which is NO. But
71 prostacyclin and endothelium-derived hyperpolarizing fac-
72 tors are also important endothelium-derived vasodilator
73 signals, with the latter prominently contributing to
74 endothelium-dependent relaxations in resistance arteries
75 [18]. The majority of studies on endothelial dysfunction
76 have concentrated on the mechanisms underlying the
77 decreased bioavailability of NO. This decrease may result
78 from a decrease in NO production, from a decrease in
79 activation of guanylyl cyclase, and/or an increase in NO
80 degradation (Fig. 2). A decrease in NO production may
81 result from a deficiency in substrates and cofactors for NO
82 sythases (NOS), such as L-arginine or tetrahydrobiopterin
83 (BH4) [13, 19]; from a decreased expression and presence
84 of endothelial NOS (eNOS) [20]; from a decreased
85 activation of NOS, such as phosphorylation of the enzyme
86or interactions with proteins (e.g., heat shock protein 90 or
87calmodulin) [20]; or from an increased presence of
88endogenous inhibitors of NOS, asymmetric dimethyl
89arginine in particular [21] (Fig. 2). An increase in NO
90degradation can result from the binding of NO to molecules
91such as hemoglobin and albumin, or from increased
92inactivation of NO by its interaction with superoxide anions
93[22]—a reaction which leads to the production of perox-
94ynitrite, a toxic vascular oxidant that further contributes to
95vasoconstriction and vascular injury (Fig. 2). Animal and
96clinical studies indicate that hypertension is associated with
97an increase in the production of reactive oxygen species
98(ROS), together with a decreased level of endogenous
99antioxidants [23–25]. The ability of vitamin C to restore
100NO production and improve endothelial function in
101essential hypertensive patients suggests a role of oxidative
102stress in endothelial dysfunction in humans [25].
103Endothelium-derived contracting factors
104The endothelial cells can produce several EDCFs, including
105angiontensin II, endothelin-1, dinucleotide uridine adeno-
106sine tetrahosphate (UP4A), cyclooxygenase (COX)-derived
107prostanoids, and ROS [5, 26]. When these endothelium-
108derived vasoconstrictors are overproduced, such as in
109hypertension or diabetes, they oppose the vasodilator
110effects of the EDRFs, exacerbating endothelial dysfunction.
111Angiotensin II
112Angiotensin I is metabolized into angiotensin II by
113endothelial angiotensin-converting enzyme (ACE). Angio-
114tensin II can activate angiotensin receptors and trigger an
115increase in cytosolic calcium to mediate contractions [27].
116In addition to causing vasoconstriction, angiotensin II can
117enhance the production of ROS—predominately through
118the activation of membrane-bound nicotinamide adenine
119dinucleotide and nicotinamide adenine dinucleotide phos-
120phate oxidases—and thus, impairs NO bioavailability [28].
121Furthermore, angiotensin II can directly stimulate the
122production and release of endothelin-1 and thus aggravate
123endothelial dysfunction [29].
124Endothelin-1
125There are three isoforms of endothelin (identified as ET-1,
126ET-2, and ET-3) that activate two subtypes of receptors (ETA
127and ETB) [30]. ETA and ETB receptors are found in the
128vascular smooth muscle and are coupled to a Gq-protein that
129leads to IP3 formation [30]. IP3 stimulates calcium release
Q2 Fig. 1 In healthy arteries, a normal vascular tone is maintained by the
balanced release of EDRF and EDCF. This balance is tipped in
hypertensive arteries with an increase in the release of EDCF and a
decrease in the release of EDRF, favoring contractions. EC endothelial
cell, SMC smooth muscle cell
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130 from the sarcoplasmic reticulum, which contributes to the
131 contraction of the vascular smooth muscle [30]. Because of
132 its powerful vasoconstrictor properties, and the retention of
133 sodium that it causes, endothelin-1 (the main isoform
134 produced by endothelial cells) increases arterial blood
135 pressure. ETB receptors are primarily located on endothelial
136 cells, and when stimulated, they increase the release of NO
137 and augment natriuresis and diuresis, thus lowering blood
138 pressure [31]. The distribution of endothelin receptors on
139 endothelial and smooth muscle cells helps to explain the
140 phenomenon that systemic administration of endothelin-1
141 causes an initial transient vasodilatation (endothelial ETB
142 activation) and hypotension, followed by prolonged vaso-
143 constriction and hypertension (ETA and ETB activation of
144 vascular smooth muscle). Endothelin-1 can also induce the
145 secondary release of cyclooxygenase-dependent EDCFs
146 (presumably endoperoxides and thromboxane A2) that cause
147 the activation of thromboxane A2/prostanoid (TP) receptors
148 of vascular smooth muscle [32–34].
149 Uridine adenosine tetraphosphate
150 UP4A is a non-peptidic dinucleotide endothelium-derived
151 vasoconstrictor that is assumed to play a role in the
152 regulation of vascular tone [35]. UP4A possesses both purine
153 and pyrimidine moieties, and the contraction that it causes is
154 mediated predominately through P2X1, and probably also
155 through P2Y2 and P2Y4 purinoceptors. UP4A is released
156 from the endothelium in response to acetylcholine,
157endothelin-1, the calcium ionophore A23187, adenosine,
158and uridine triphosphate [35]. The role of UP4A in the
159pathogenesis of hypertension is yet to be determined.
160COX-derived EDCFs
161The importance of COX-derived vasoconstrictor prostanoids
162has gained significant recognition in the past decade. The
163production of endothelium-derived prostanoids is augmented
164in arteries with regenerated endothelium [36, 37], and in
165normotensive aging and hypertensive arteries [5, 7, 9, 38].
166The endothelium of the renal arteries of healthy rats also
167releases EDCF, suggesting that it may play a role in the
168regulation of basal tone in this artery, and not only during
169agonist-induced stimulated release [39, 40]. Studies in
170humans show that the acetylcholine-induced vasodilatation
171is diminished in conductance and resistance vessels of patients
172with hypertension. In these hypertensive patients, intra-arterial
173administration of the COX inhibitor indomethacin improved
174the vasodilator response to acetylcholine [41, 42], suggesting
175that the production of COX-derived EDCF contributes to the
176onset of endothelial dysfunction in human hypertension.
177Mechanisms underlying the production of COX-derived
178EDCFs
179In brief, the chain of events leading to endothelium-
180dependent contractions requires an abnormal increase in
Fig. 2 Decreased bioavailabili-
ty of nitric oxide may result
from a decrease in NO produc-
tion, an increase in NO degra-
dation, or a decrease in the
activation of guanylyl cyclase.
Decreased NO production may
result from deficiency in sub-
strates and cofactors for nitric
oxide synthase (NOS), de-
creased expression of NOS, de-
creased activation of NOS, or an
increase in endogenous inhibi-
tors of NOS. An increase in NO
degradation can result from the
binding of NO to molecules
such as superoxide anions, he-
moglobin, and albumin. ADMA
asymmetric dimethyl arginine,
BH4 tetrahydrobiopterin, EC
endothelial cell, hsp90 heat
shock protein 90, NOS nitric
oxide synthase, O2, ONOO
peroxynitrite, P phosophoryla-
tion, SMC smooth muscle cell
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181 intracellular calcium in the endothelial cells [5, 26]. The
182 rise in calcium activates phospholipase A2 to release
183 arachidonic acid from the cell membrane phospholipids.
184 Then COX breaks down arachidonic acid to form
185 prostanoids that activate TP receptors located in the
186 vascular smooth muscle, resulting in contraction [5, 26].
187 During the production of prostanoids, COX simultaneous-
188 ly produces ROS, which can subsequently stimulate COX
189 within the smooth muscle and produce more prostanoids
190 [5, 26], thus amplifying the TP receptor-mediated re-
191 sponse (Fig. 3).
192 Calcium overload
193 An abnormal, high accumulation of intracellular calcium in
194 endothelial cells is critical and triggers the production of
195 COX-derived EDCFs [43] (Fig. 3). Stimulation with acetyl-
196 choline results in calcium overload in the aortic endothelial
197 cells of SHR, but not in normotensive Wistar Kyoto rats
198 (WKY), signifying dysfunction of calcium handling in the
199 hypertensive strain [43]. When calcium overload is mimicked
200 in WKYarteries using calcium-increasing agents (such as the
201 calcium ionophore A23187 or cyclopiazonic acid),
202 endothelium-dependent contractions are evoked despite the
203 normal arterial blood pressure of the animals. Nonetheless,
204 the amplitude of the contraction remains larger in SHR than
205 in WKY [43]. This is explained best by the increased
206 expression of COX and prostanoid synthases, a greater
207release of prostanoids, as well as a hyper-responsiveness of
208the TP receptors in the aortas of SHR than in that of WKY
209[5, 44–46]. Hence, all these downstream modifications are
210not a prerequisite for the development of endothelium-
211dependent contractions, but their presence amplifies the
212response.
213COX activity
214The activity of COX is required for the generation of
215vasoconstrictor prostanoids. Two isoforms of COX, a
216constitutive form (COX1) and an inducible form (COX2),
217have been cloned and characterized [47]. Yet COX1—
218termed as the constitutive isoform—can be over-expressed
219under certain conditions, such as increases in shear stress
220[47]. Inflammation is the most common cause for the up-
221regulation of COX2 [47]. Multiple studies using arteries
222from mice and rats have confirmed that COX1 is the
223primary isoform involved in endothelium-dependent con-
224tractions. For example, endothelium-dependent contractions
225are abolished by selective COX1 inhibitors, but are
226relatively insensitive to selective COX2 inhibitors [9, 48].
227Furthermore, endothelium-dependent contractions occur in
228the aortas of wild-type and COX2−/− knockout mice, but
229not in those of COX1−/− knockout mice [49]. Later studies
230using hamster aortas [50] and aging rats [51], however,
231showed that COX2 can contribute equally to the contraction
232when present or induced in the endothelial cells.
Fig. 3 Endothelium-dependent
contraction has two compo-
nents: the generation of prosta-
glandins and ROS. A rise in
calcium activates phosopholi-
pase A2 (PLA2) to release
arachidonic acid, which is sub-
sequently metabolized by
cyclooxygenase (COX) to form
endoperoxides and various
prostaglandins that activate TP
receptors located at the vascular
smooth muscle. COX also pro-
duces ROS, which diffuses or
possibly transmigrates via gap
junctions and stimulates COX
within the smooth muscle, pro-
ducing more prostanoids and
amplifying TP receptor-
mediated contractions. ADP
adenosine diphosphate, m mus-
carinic receptors, P purinergic
receptors, PGE2 prostaglandin
E2, PGF2a prostaglandin F2a;
PGI2 prostacyclin, ROS reactive
oxygen species, TXA2 throm-
boxane A2
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233 Production of prostanoids
234 The immediate products of COX are the endoperoxides,
235 which themselves function as vasoconstrictors by binding
236 to TP receptors [45]. Endoperoxides are further transformed
237 into prostacyclin, thromboxane A2, prostaglandin E2,
238 prostaglandin F2a, and prostaglandin D2 by their respective
239 prostanoid synthases (Fig. 3). Prostacyclin synthase is by
240 far the most abundant prostanoid synthase expressed in the
241 endothelium [52]. Its expression is augmented in the aorta
242 of SHR compared with that of WKY [52, 53], suggesting
243 that chronic hypertension induces the protein. In line with
244 this observation, there is an exaggerated release of
245 prostacyclin in the aorta of the hypertensive rat [46, 54,
246 55]. Since this classical vasodilator prostanoid does not
247 mediate relaxation in this artery, it instead evokes contrac-
248 tion through activation of TP receptors at high concen-
249 trations [44]. In response to acetylcholine, prostacyclin and
250 endoperoxides are the key mediators of endothelium-
251 dependent contractions in the rat aorta [5, 44]. Whether or
252 not prostacyclin plays a detrimental role as EDCF in other
253 animal models or in humans remains to be demonstrated.
254 Under certain pathological conditions involving en-
255 hanced oxidative stress, ROS interacts with NO to form
256 peroxynitrite [22], which can significantly inhibit the
257 activity of prostacyclin synthase by tyrosine nitration of
258 the enzyme [56, 57]. Under such circumstances, there is a
259 marked compensatory production of prostaglandin E2 and
260 prostaglandin F2a, leading to greater importance of these
261 two prostanoids [46, 56, 58]. In the hamster aorta and in
262 human renal arteries, there is a high expression of COX2
263 and a prominent release of prostaglandin F2a, indicating the
264 importance of this prostanoid as the EDCF in these arteries
265 [50]. Likewise, prostaglandin F2a is the major EDCF
266 released from re-endothelized femoral rat arteries [36].
267 When endothelium-dependent contractions are evoked
268 by the calcium ionophore A23187 or adenosine diphos-
269 phate (ADP) in the aorta of SHR, the response is partly
270 sensitive to inhibitors of thromboxane synthase [54, 55,
271 59], implying the involvement of thromboxane A2. The
272 mRNA expression of thromboxane synthase is enhanced in
273 the aorta of SHR compared to WKY [52]. Direct chemical
274 detection with immunoassays has revealed that A23187 and
275 ADP stimulate the release of thromboxane A2 and
276 endoperoxides [46, 54, 55], suggesting that these prosta-
277 noids are the key mediators of endothelium-dependent
278 contraction during exposure to these agonists.
279 On the whole, there is a marked heterogeneity in the
280 formation of EDCF. The precise chemical identity of EDCF
281 varies depending on the stimulus, the vascular bed, the age,
282 and the physiopathological condition of the donor animal.
283 Thus, prostacyclin, thromboxane A2, prostaglandin E2,
284 prostaglandin F2a, and ROS all have been proposed as
285COX-derived EDCF. It is important to keep in mind that
286endothelium-dependent contractions are unlikely to be due
287a single substance, but rather likely are evoked by a mixture
288of these endothelium-derived products (Fig. 3).
289The involvement of TP receptors
290Prostanoid receptors are classified into five discrete types
291based on their sensitivity to the five naturally occurring
292prostanoids: prostacyclin I2, thromboxane A2, prostaglandin
293D2, prostaglandin E2, and prostaglandin F2a. They are
294termed P receptors—IP, TP, DP, EP, and FP—with the
295preceding letter indicating the prostanoid to which they are
296the most sensitive. The effectiveness of TP receptor
297inhibitors in abolishing endothelium-dependent contrac-
298tions pinpoints the involvement of this prostanoid receptor
299subtype in the response [48, 60–62]. Although thrombox-
300ane A2 is the most potent agonist towards TP receptors, it is
301not its exclusive ligand. All other prostanoids can bind to
302TP receptors and mediate contraction, but with varying
303potency. The mRNA and protein expression of TP receptors
304does not differ in the aortas of WKY and SHR, indicating
305that their expression level is not altered by the hypertensive
306process [52, 63]. However, the vascular smooth muscle of
307the SHR aorta exhibits a greater responsiveness than that of
308the WKY to the constrictor effect of endoperoxides acting
309at TP receptors [45]. An involvement of other prostanoid
310receptors in endothelium-dependent contractions has been
311suggested [63–65], but non-TP receptor endothelium-
312dependent component appears to constitute a small part of
313the full response.
314A separate ROS component
315During the production of prostanoids by endothelial COX,
316ROS are formed simultaneously. These COX-derived ROS
317can act as vasoconstrictors [43, 62]. Thus, COX-derived
318EDCF-mediated contractions can be attributed to two
319components—prostanoids or ROS [5] (Fig. 3). The possible
320existence of a separate ROS component in endothelium-
321dependent contractions is strengthened by the following
322observations: First, that the generation of ROS by xanthine
323plus xanthine oxidase in the extracellular bathing fluid
324evokes a contraction in the aorta without endothelium that
325requires the activity of COX and stimulation of TP
326receptors [62, 66], suggesting that endothelium-derived
327ROS could stimulate COX in the vascular smooth muscle
328with resulting prostanoid production, causing more TP
329receptor-mediated contraction. Second, the direct applica-
330tion of hydrogen peroxide, but not that of superoxide
331anions or hydroxyl radicals, triggers contractions in the rat
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332 aorta that are sensitive to cyclooxygenase inhibitors and TP
333 receptor antagonists [66–69], suggesting that hydrogen
334 peroxide is the mediator responsible for the ROS compo-
335 nent of endothelium-dependent contraction. Myoendothe-
336 lial gap junctions may facilitate the transfer of ROS from
337 endothelial cells to smooth muscle cells [70]. In the aorta of
338 the SHR, both the prostanoid and ROS component appear
339 to contribute equally to the final endothelium-dependent
340 contractions, as antioxidants only partly reduce the re-
341 sponse [62]. By contrast, in the canine basilar artery,
342 endothelium-dependent contractions are fully prevented by
343 superoxide dismutase plus catalase [71], indicating that the
344 response is dominated by the endothelial ROS component.
345 Therapeutic interventions to improve endothelial
346 function in hypertension
347 Considering the marked endothelial dysfunction in hyper-
348 tension and since its severity correlates with the develop-
349 ment of coronary artery disease and predicts future
350 cardiovascular events [72], this dysfunction has to be
351 considered as a central target in the treatment of hyperten-
352 sion. Theoretically, drugs targeted to increase the release of
353 EDRF (and in particular, NO), and drugs that decrease the
354 production or action of EDCF, should reduce endothelial
355 dysfunction.
356 Improving NO production
357 Direct NO releasing compounds, such as nitroglycerin, are
358 effective vasodilators. However, continuous administration
359 comprises a clinical problem due to the desensitization of
360 the target enzyme guanylyl cyclase, leading to cross-
361 tolerance to other endothelium-dependent vasodilators
362 [73]. Other concerns involve the ability of nitroglycerin to
363 increase ROS indirectly [74].
364 Acute supplementation with BH4, an essential cofactor
365 of NOS, improves endothelial dysfunction by increasing
366 NO and reducing ROS in many experimental animal studies
367 [75]. But a clinical trial of the effects of BH4 on arterial
368 blood pressure in subjects with poorly controlled systemic
369 hypertension has been terminated for lack of significant
370 beneficial effect [76]. By contrast, positive results have
371 been reported with the use of BH4 to treat endothelial
372 dysfunction in patients with sickle-cell disease [76]. The
373 dissimilar results in these clinical trials highlight the
374 importance of fully addressing basic questions about
375 the mechanism of endothelial regulation that will be critical
376 in the design of BH4-based therapies.
377 Endogenous NO formation is largely dependent on the
378 extracellular concentrations of its substrate, L-arginine.
379 Supplementation of L-arginine leads to a measurable
380decline in blood pressure and improved endothelial func-
381tions in experimental animals and in hypertensive patients
382[77, 78]. Most L-arginine studies to date have used high
383daily doses, due to the pharmacokinetics of oral L-arginine,
384which reaches its highest concentration in the blood within
385an hour and then diminishes quickly [77]. The use of
386sustained-release L-arginine products in hypertensive
387patients shows promising signs of improving endothelial
388function [79].
389When arteries are exposed to NO, whether released from
390the endothelial cells or added exogenously, this causes a
391long-term inhibition of endothelium-dependent contractions
392[80–83]. This implies a suppressed occurrence of EDCF-
393mediated contractions under conditions where there is an
394adequate release of NO. Thus, NO-enhancing agents not
395only will enhance vasodilatation, but also will hamper the
396occurrence of endothelium-dependent contractions.
397Reducing arterial blood pressure
398Antihypertensive treatments—such as ACE inhibitors,
399calcium channel blockers, and third generation β-
400blockers—reverse endothelial dysfunction in experimental
401animals and in hypertensive patients [84, 85]. Several
402effects of ACE inhibitors enhance NO release and
403bioactivity, including preventing the breakdown of endog-
404enous bradykinin (a potent NO releaser) [85]. ACE
405inhibitors also protect NO bioavailability [85]. The
406beneficial effect of calcium channel blockers on endothe-
407lial dysfunction can be attributed to their ability to reduce
408calcium entry through voltage-dependent channels of the
409vascular muscle cells, thereby dilating large conduit and
410resistance arteries [86]. In addition, drugs such as amlodi-
411pine activate eNOS to release more NO [87, 88]. Other
412calcium channel blockers, such as lacidipine, possess
413antioxidant properties [89], while third-generation β-
414blockers such as carvedilol and nebivolol, in addition to
415their adrenergic blocking characteristics, substantially im-
416prove endothelial dysfunction through their strong stimula-
417tory effect on the activity of endothelial NOS and their
418antioxidative properties [90]. Blood pressure reduction per se
419does not guarantee improvement in endothelial dysfunction.
420Other antihypertensive drugs, such as conventional β-
421adrenergic blockers, reduce arterial blood pressure but fail
422to restore normal endothelial function [85].
423Preventing EDCF-mediated responses
424Because prostacyclin is one of the main mediators of
425endothelium-dependent contractions in the response of
426acetylcholine, inhibition of its production may result in
427the improvement of endothelial function. But prostacy-
428clin also is beneficial to the vascular system because of
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429 its ability to prevent aggregation of platelets and avoid
430 thrombosis [91]. In addition, inhibition of prostacyclin
431 synthase results in the build-up of endoperoxides (which
432 by themselves activate TP receptors) and the shunting
433 of the latter to other synthases, which produce more
434 potent vasoconstrictor prostanoids [46, 54, 55]. There-
435 fore, selective inhibition of prostacyclin synthase would
436 not reduce the occurrence of unwanted endothelium-
437 dependent contractions, but rather would result in ampli-
438 fied worsening of the vascular complications. In the SHR
439 aorta, thromboxane A2, and endoperoxides are the main
440 EDCF in response to A23187 and adenosine diphosphate
441 [44, 54, 55]. In the aorta of the hamster, in response to
442 acetylcholine, the main EDCF is prostaglandin F2a [50].
443 Thus, the contribution of various prostaglandins released
444 during endothelium-dependent contractions varies
445 depending on the stimulus, the artery, the species, and
446 the disease state of the donor. It therefore appears more
447 desirable to design drugs that target either upstream or
448 downstream of the EDCF cascade, rather than individual
449 prostanoid synthases, to alleviate EDCF-mediated endo-
450 thelial dysfunction.
451 Depending on the availability of the enzyme, both
452 COX1 and COX2 can contribute to endothelium-
453 dependent contractions. Thus, the use of selective drugs
454 targeting a specific isoform of COX is not the rationale of
455 choice to inhibit endothelium-dependent contractions in
456 hypertension. Moreover, the use of non-selective COX
457 inhibitors are linked with multiple adverse effects, includ-
458 ing peptic ulceration and dyspepsia, while selective COX-2
459 inhibition increases the risk of myocardial infarction,
460 thrombosis, and stroke [92].
461 EDCFs ultimately converge to activate TP receptors [48,
462 60–62]. Although other prostanoid receptors may contrib-
463 ute [63–65], it seems—at least from data obtained in animal
464 studies—that TP receptors are the dominant receptor
465 subtype involved. The TP receptor blocker terutroban
466 improves endothelial function in patients with coronary
467 disease [93], which illustrates the role of vasoconstrictor
468 prostanoids in human endothelial dysfunction. Thus, selec-
469 tive TP receptor antagonists may be the most logical
470 therapeutic tools to intervene with endothelium-dependent
471 contractions in hypertension. Epoxyeicosatrienoic and
472 dihydroxyeicosatrienoic acids function as endogenous TP-
473 receptor antagonists and induce vasodilatation [94], sug-
474 gesting their use as novel TP receptor inhibitors. Synthetic
475 TP receptor blockers (such as terutroban) effectively
476 prevent endothelium-dependent contraction in numerous
477 hypertensive experimental animal models [7, 48, 51, 60–
478 62]. The prospective use of TP-receptor antagonists in
479 correcting the consequences of the imbalanced release of
480 endothelium-derived vasoactive substances in hypertensive
481 patients deserves further exploration.
482Conclusion
483The endothelium is one of the major target organs that are
484damaged by high blood pressure. Chronic elevation in blood
485pressure accelerates the turnover of endothelial cells, causing
486them to age prematurely. The regenerated endothelium has an
487impaired ability to release EDRF and favors the occurrence of
488endothelium-dependent contractions. Endothelial dysfunction
489triggers a chain of undesired responses, including increased
490platelet aggregation, expression of adhesion molecules, and
491vascular muscle growth—ultimately leading to thrombosis,
492inflammation, vascular remodeling, and atherosclerosis. En-
493dothelial dysfunction therefore should be considered as a
494central target in the treatment of hypertension. Mechanisms
495that increase EDRF or decrease the release/bioavailability
496action of EDCF are promising drug targets to mitigate the
497damage caused by endothelial dysfunction.
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